Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Journal of Theoretical Biology
|
May 9, 2008
Human uniqueness-self-interest and social cooperation
Daijiro Okada, Paul M Bingham
International Journal of Molecular Sciences
|
September 28, 2023
Toward a Unifying Hypothesis for Redesigned Lipid Catabolism as a Clinical Target in Advanced, Treatment-Resistant Carcinomas
Paul M Bingham, Zuzana Zachar
Evolutionary Anthropology
|
June 19, 2013
Theory testing in prehistoric North America: fruits of one of the world's great archeological natural laboratories
Paul M Bingham, Joanne Souza
Evolutionary Anthropology
|
June 19, 2013
Introduction: social complexity and the bow in the prehistoric North American record
Paul M Bingham, Joanne Souza, John H Blitz
Expert Review of Clinical Pharmacology
|
October 7, 2014
Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy
Paul M Bingham, Shawn D Stuart, Zuzana Zachar
AJR. American Journal of Roentgenology
|
May 3, 2017
Metabolic PET Imaging in Oncology
Kiran Kumar Solingapuram Sai, Zuzana Zachar, Paul M Bingham, et al.
Plos One
|
June 8, 2022
Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613
Moises O Guardado Rivas, Shawn D Stuart, Daniel Thach, et al.
Cancer & Metabolism
|
March 12, 2014
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process
Shawn D Stuart, Alexandra Schauble, Sunita Gupta, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
July 20, 2011
Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo
Zuzana Zachar, James Marecek, Claudia Maturo, et al.
The Lancet. Oncology
|
May 13, 2017
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Angela Alistar, Bonny B Morris, Rodwige Desnoyer, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Journal of Theoretical Biology
|
May 9, 2008
Human uniqueness-self-interest and social cooperation
Daijiro Okada, Paul M Bingham
International Journal of Molecular Sciences
|
September 28, 2023
Toward a Unifying Hypothesis for Redesigned Lipid Catabolism as a Clinical Target in Advanced, Treatment-Resistant Carcinomas
Paul M Bingham, Zuzana Zachar
Evolutionary Anthropology
|
June 19, 2013
Theory testing in prehistoric North America: fruits of one of the world's great archeological natural laboratories
Paul M Bingham, Joanne Souza
Evolutionary Anthropology
|
June 19, 2013
Introduction: social complexity and the bow in the prehistoric North American record
Paul M Bingham, Joanne Souza, John H Blitz
Expert Review of Clinical Pharmacology
|
October 7, 2014
Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy
Paul M Bingham, Shawn D Stuart, Zuzana Zachar
AJR. American Journal of Roentgenology
|
May 3, 2017
Metabolic PET Imaging in Oncology
Kiran Kumar Solingapuram Sai, Zuzana Zachar, Paul M Bingham, et al.
Plos One
|
June 8, 2022
Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613
Moises O Guardado Rivas, Shawn D Stuart, Daniel Thach, et al.
Cancer & Metabolism
|
March 12, 2014
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process
Shawn D Stuart, Alexandra Schauble, Sunita Gupta, et al.
Journal of Molecular Medicine (Berlin, Germany)
|
July 20, 2011
Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo
Zuzana Zachar, James Marecek, Claudia Maturo, et al.
The Lancet. Oncology
|
May 13, 2017
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Angela Alistar, Bonny B Morris, Rodwige Desnoyer, et al.
Page
of 1